74 completed, 36 terminated, 23 recruiting, 22 active not recruiting. 179 Phase 2, 28 Phase 1, 10 Phase 3.
Follow Folinic Acid: new trials by email Literature Review of Folinic Acid trials Research Report on Folinic Acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Northwestern University | 125 | 2026-10-26 | 2026-10-29 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| A Placebo-controlled Trial of Folinic Acid in Children With ASD Folinic Acid, Placebo - Autism Spectrum Disorder | Phase 2 | Recruiting | Prof. Adi Aran | 150 | 2026-06-23 | 2026-06-22 |
| A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies Adagrasib, Pembrolizumab, Cetuximab - Solid Tumors | Phase 2 | Recruiting | Mirati Therapeutics Inc. | 170 | 2026-05-06 | 2026-10-27 |
| NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial Biospecimen Collection, Computed Tomography, Fluorouracil - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 20 | 2026-03-02 | 2026-09-21 |
| Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Roswell Park Cancer Institute | 35 | 2026-02-16 | 2026-08-19 |
| Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer Oxaliplatin intravenous, 5 FU bolus, Folinic acid - Metastatic Colorectal Carcinoma (mCRC) | Phase 2 | Not yet recruiting | Federation Francophone de Cancerologie Digestive | 74 | 2025-12-31 | 2025-09-08 |
| NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer Oxaliplatin, Irinotecan, Folinic Acid - Pancreatic Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 20 | 2025-09-04 | 2026-05-05 |
| Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors Nanoliposomal irinotecan, Oxaliplatin, 5 fluorouracil - Small Bowel Adenocarcinoma | Phase 2 | Recruiting | Tiago Biachi de Castria | 36 | 2025-06-30 | 2026-07-28 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-27 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-27 |
| FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery Balstilimab, Biospecimen Collection, Botensilimab - Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 26 | 2025-05-20 | 2026-06-29 |
| Folinic Acid as a Treatment for Autism Spectrum Disorder in Children Folinic Acid, Placebo - Autism Spectrum Disorder | Phase 2 | Recruiting | KK Women's and Children's Hospital | 184 | 2025-05-19 | 2026-06-05 |
| Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer Conventional Radiotherapy, Capecitabine, 5-fluorouracil - Locally Recurrent Rectal Cancer | Phase 2 | Recruiting | Fudan University | 221 | 2025-03-10 | 2025-04-15 |
| A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Telisotuzumab Adizutecan, Budigalimab, Fluorouracil - Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Active not recruiting | AbbVie | 185 | 2024-12-13 | 2026-07-21 |
| Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 24 | 2024-12-06 | 2026-06-18 |
| Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine - Gastroesophageal Junction, Gastroesophageal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 160 | 2024-09-20 | 2026-10-07 |
| HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer HR070803, Oxaliplatin, Tegafur - Efficacy and Safety | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 120 | 2024-04-20 | 2024-04-25 |
| Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer Irinotecan liposome injection, Oxaliplatin, 5-Fluorouracil - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 96 | 2024-04-01 | 2024-03-15 |
Showing 20 of 179. Sign in to see all of them.
Colorectal Neoplasms (40) · Pancreatic Neoplasms (24) · Stomach Neoplasms (15) · Esophageal Neoplasms (14) · Rectal Neoplasms (13) · Burkitt Lymphoma (12) · Neoplasms (12) · Colonic Neoplasms (11) · Neoplasm Metastasis (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Autism Spectrum Disorder (7) · Adenocarcinoma Of Esophagus (6) · Adenocarcinoma (4) · Cholangiocarcinoma (4) · Gallbladder Neoplasms (4)
National Cancer Institute (NCI) (17) · M.D. Anderson Cancer Center (8) · Hoffmann-La Roche (5) · Children's Oncology Group (4) · Ludwig-Maximilians - University of Munich (4) · Roswell Park Cancer Institute (4) · UNICANCER (4) · University of Miami (4) · AbbVie (3) · City of Hope Medical Center (3) · Dana-Farber Cancer Institute (3) · Mayo Clinic (3) · NuCana plc (3) · SCRI Development Innovations, LLC (3) · St. Jude Children's Research Hospital (3)
United States (117) · France (20) · Germany (19) · Spain (18) · Canada (15) · Australia (14) · United Kingdom (14) · Italy (12) · Puerto Rico (11) · South Korea (10) · Belgium (9) · China (8) · Taiwan (8) · Israel (5) · Norway (5)
Christos Fountzilas (2) · David R. Spigel, MD (2) · Dominik Modest, PD Dr. (2)
PMID 33735476, PMID 40341124, PMID 15476202, PMID 18759768, PMID 18985718, PMID 19064966, PMID 20038221, PMID 20084109, PMID 21775070, PMID 22835045, PMID 23063354, PMID 23293700, PMID 23493136, PMID 24556041, PMID 25122693, PMID 25232828, PMID 25304612, PMID 25926352, PMID 27091810, PMID 27194176, PMID 27401892, PMID 27752075, PMID 28246207, PMID 28275117, PMID 28448662, PMID 29549862, PMID 29618479, PMID 29812996, PMID 30422156, PMID 30552157, PMID 31142037, PMID 32029495, PMID 32469386, PMID 32790844, PMID 32816630, PMID 32883216, PMID 32939319, PMID 33242441, PMID 33337539, PMID 33835977, PMID 34001462, PMID 34196693, PMID 34492682, PMID 34817733, PMID 34980020, PMID 35007127, PMID 35622074, PMID 35920133, PMID 36115002, PMID 36221952
2017 (5), U10CA180888 (5), U10CA180820 (4), U10CA180886 (4), 2009 (3), 2023 (3), 2015 (2), 2016 (2), P30CA016672 (2), P30CA033572 (2), P30CA036727 (2), U10CA032102 (2), U10CA180821 (2), U10CA180868 (2), 2008 (1)